Table 3.
Relationship between the expression level of hsa-let-7c, hsa_circ_0001324 and hsa_circ_0001483 in gastric cancer patients and clinicopathological factors
| Variability | Patient Number | hsa_circ_0001324(ΔCt ) p50(p25, p75) | P(2 -ΔCt) | Patient Number | hsa_circ_0001483(ΔCt ) p50(p25, p75) | P(2 -ΔCt) | Patient Number | hsa-let-7c(2 -ΔCt) p50(p25, p75) | P(2 -ΔCt) |
|---|---|---|---|---|---|---|---|---|---|
| Gender | 0.910 | 0.189 | 0.901 | ||||||
| Male | 42 | 12.36 (11.41, 13.77) | 42 | 18.20 (17.40, 19.68) | 16 | 3.76 (0.98, 10.39) | |||
| Female | 24 | 12.41 (11.15, 13.37) | 24 | 19.11 (17.78, 20.61) | 14 | 2.50 (1.21, 28.84) | |||
| Age | 0.005 | 0.586 | 0.917 | ||||||
| ≥60 | 38 | 12.65 (11.81, 14.10) | 38 | 18.93 (17.51, 20.37) | 13 | 2.35 (1.11, 14.06) | |||
| <60 | 28 | 11.40 (10.77, 12.82) | 28 | 18.30 (17.44, 20.00) | 17 | 2.97 (1.29, 16.53) | |||
| Smoking | 0.748 | 0.271 | 0.464 | ||||||
| Ever Smoker | 16 | 12.30 (11.67, 14.19) | 16 | 19.65 (17.59, 20.81) | 4 | 1.52 (0.46, 36.32) | |||
| Never Smoker | 50 | 12.43 (11.26, 13.26) | 50 | 18.27 (17.44, 19.70) | 26 | 2.97 (1.21, 12.27) | |||
| Drinking | 0.758 | 0.433 | 0.454 | ||||||
| Ever Drinker | 9 | 11.72 (11.68, 14.28) | 9 | 19.67 (17.07, 20.93) | 2 | NA | |||
| Never Drinker | 57 | 12.44 (11.26, 13.39) | 57 | 18.27 (17.50, 19.92) | 28 | 2.97 (1.16, 15.84) | |||
| Family History | 0.866 | 0.449 | 0.707 | ||||||
| Yes | 15 | 12.52 (11.22, 14.05) | 15 | 18.59 (18.24, 20.47) | 8 | 2.33 (1.46, 4.62) | |||
| No | 51 | 12.22 (11.28, 13.34) | 51 | 18.15 (17.44, 20.07) | 22 | 3.31 (0.96, 26.33) | |||
| Location | 0.767 | 0.418 | 0.891 | ||||||
| Body | 20 | 12.28 (11.29, 13.41) | 20 | 18.09 (16.94, 19.66) | 13 | 2.03 (1.28, 7.62) | |||
| Angle | 11 | 11.84 (11.11, 12.64) | 11 | 19.30 (18.47, 21.65) | 3 | NA | |||
| Antrum | 23 | 12.60 (11.24, 13.84) | 23 | 18.26 (17.78, 19.67) | 10 | 2.66 (1.40, 44.06) | |||
| Entire | 11 | 12.03 (11.31, 14.05) | 11 | 19.59 (17.00, 20.61) | 3 | NA | |||
| Macroscopic Type | 0.856 | 0.718 | 0.565 | ||||||
| Protruded Type | 3 | NA | 3 | NA | 2 | NA | |||
| Ulcerative Type | 13 | 12.44 (11.75, 12.86) | 13 | 18.60 (17.17, 20.06) | 6 | 2.15 (0.88, 16.99) | |||
| Ulcerative Infiltrative Type | 32 | 12.37 (10.72, 13.30) | 32 | 18.53 (17.88, 20.22) | 13 | 5.17 (1.57, 16.53) | |||
| Diffuse Infiltrative Type | 18 | 11.87 (11.27, 14.15) | 18 | 18.30 (16.77, 19.77) | 9 | 2.97 (1.18, 32.08) | |||
| Histological Type | 0.744 | 0.287 | 0.499 | ||||||
| Papillary Adenocarcinoma (I) | 0 | NA | 0 | NA | 0 | NA | |||
| Well Differentiated Type (II) | 1 | NA | 1 | NA | 1 | NA | |||
| Moderately Differentiated Type (III) | 8 | 12.39 (11.84, 12.90) | 8 | 18.07 (17.53, 20.10) | 2 | NA | |||
| Poorly Differentiated Type (IV) | 39 | 12.38 (11.24, 14.09) | 32 | 18.33 (17.42, 19.77) | 15 | 1.69 (1.23, 8.51) | |||
| Mucinous Adenocarcinoma (V) | 6 | 12.73 (10.91, 13.30) | 5 | 20.04 (18.57, 20.52) | 4 | 2.50 (0.92, 8.34) | |||
| Signet-ring Cell Cinoma (VI) | 10 | 11.43 (10.88, 13.07) | 9 | 17.87 (16.85, 19.18) | 6 | 26.63 (3.37, 76.49) | |||
| Lauren Classification | 0.757 | 0.915 | 0.577 | ||||||
| Intestinal | 9 | 12.33 (11.84, 12.77) | 9 | 18.15 (17.62, 19.84) | 3 | NA | |||
| Diffuse | 55 | 12.22 (11.22, 13.84) | 55 | 18.47 (17.42, 20.07) | 25 | 2.97 (1.28, 13.88) | |||
| TNM stage | 0.473 | 0.160 | 0.422 | ||||||
| I | 7 | 12.01 (10.71, 12.64) | 7 | 19.30 (18.26, 22.69) | 4 | 4.11 (0.78, 9.54) | |||
| II | 23 | 12.86 (11.11, 14.35) | 23 | 18.15 (17.34, 20.37) | 9 | 10.13 (1.34, 55.27) | |||
| III | 36 | 12.22 (11.34, 13.30) | 36 | 18.30 (17.44, 19.70) | 17 | 2.03 (1.18, 6.84) | |||
| IV | 0 | NA | 0 | NA | 0 | NA | |||
| 0.606 | 0.575 | 0.315 | |||||||
| I+II | 30 | 12.54 (11.07, 13.95) | 30 | 18.54 (17.51, 21.06) | 13 | 6.73 (1.24, 29.72) | |||
| III+IV | 36 | 12.22 (11.34, 13.30) | 36 | 18.30 (17.44, 19.70) | 17 | 2.03 (1.18, 6.84) | |||
| Peritumoral Inflammatory Cells | 0.685 | 0.03 | 0.159 | ||||||
| + | 18 | 11.97 (11.29, 12.89) | 18 | 17.80 (16.85, 18.68) | 9 | 8.51 (2.66, 42.26) | |||
| ++ | 26 | 12.41 (11.02, 13.42) | 26 | 19.30 (18.15, 20.62) | 0.02 | 11 | 1.69 (0.99, 5.17) | ||
| +++ | 21 | 12.60 (11.42, 14.15) | 21 | 18.32 (17.40, 20.43) | 9 | 1.44 (1.00, 10.30) | |||
| Lymphovascular invasion | 0.931 | 0.984 | 0.485 | ||||||
| + | 42 | 12.37 (11.26, 13.77) | 42 | 18.33 (17.43, 20.15) | 18 | 2.19 (1.10, 8.91) | |||
| - | 24 | 12.36 (11.35, 13.29) | 24 | 18.43 (17.48, 20.20) | 12 | 4.85 (1.36, 33.11) | |||
| Ganglion invasion | 0.352 | 0.375 | 0.518 | ||||||
| + | 53 | 12.09 (11.23, 13.74) | 53 | 18.32 (17.37, 20.38) | 23 | 2.97 (1.34, 22.94) | |||
| - | 12 | 12.58 (12.09, 13.51) | 12 | 18.53 (18.06, 19.59) | 6 | 4.11 (0.79, 10.22) | |||
| Lymphatic metastasis | 0.332 | 0.044 | 0.944 | ||||||
| + | 45 | 12.22 (11.25, 13.39) | 45 | 18.27 (17.42, 19.67) | 22 | 2.19 (1.21, 12.00) | |||
| - | 21 | 12.64 (11.66, 13.76) | 21 | 19.30 (17.87, 22.14) | 8 | 4.85 (0.78, 19.83) | |||
| Depth of invasion | 0.583 | 0.264 | 0.937 | ||||||
| Mucous Layer (pT1) | 2 | NA | 2 | NA | 1 | NA | |||
| Submucosal Layer (pT2) | 5 | 11.48 (10.34, 12.68) | 5 | 18.03 (17.06, 18.10) | 3 | NA | |||
| Muscular Layer (pT3) | 7 | 12.52 (11.11, 12.86) | 7 | 18.88 (18.47, 22.69) | 3 | NA | |||
| Subserosa Layer (pT4) | 1 | NA | 1 | NA | 0 | NA | |||
| Serosal Layer or Invasion Adjacent Organs(pT5) | 51 | 12.52 (11.28, 14.09) | 43 | 18.32 (17.40, 20.37) | 23 | 2.35 (1.23, 22.94) | |||
| 0.340 | 0.263 | 0.845 | |||||||
| pT1+pT2 | 7 | 1201 (10.37, 12.44) | 7 | 18.04 (17.45, 18.26) | 4 | 2.23 (1.02, 5.79) | |||
| pT3+pT4 | 8 | 12.18 (11.19, 12.81) | 8 | 19.09 (18.50, 21.86) | 3 | NA | |||
| pT5 | 51 | 12.52 (11.28, 14.09) | 51 | 18.32 (17.40, 20.37) | 23 | 2.34 (1.23, 22.94) | |||
| Growth Pattern | 0.904 | 0.938 | 0.067 | ||||||
| Massive or Nested | 11 | 12.52 (10.31, 13.34) | 11 | 18.15 (17.78, 20.38) | 26 | 3.63 (1.31, 18.96) | |||
| Diffuse Infiltrative or Infiltralive | 55 | 12.22 (11.28, 13.67) | 55 | 18.47 (17.42, 20.07) | 4 | 1.17 (0.45, 1.89) |
Note: CON, control; GC, gastric cancer. The higher ΔCt value indicates a lower expression while the higher 2-ΔCt value means the higher expression level.